Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome.

When TMB was adjusted for a multivariable Cox regression analysis in the whole cohort, BAF/PBAF gene mutations remained an independent prognostic factor for OS in patients treated ICI (Table 1 ). The presence of BAF/PBAF gene mutations was associated with improved outcome on immunotherapy in almost all carcinomas types except in non-small cell lung cancer (NSCLC), unknown primary carcinoma and renal cancer even if the effect for some cancer types did not reach statistical significance, due to limited sample size.

also in 111,027 other papers